IYIrina Yermilov

Irina Yermilov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irina Yermilov has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America

    by Robert A. Hegele, Zahid Ahmad, Ambika Ashraf, Andrew Baldassarra, Alan S. Brown, Alan Chait, Steven D. Freedman, Brenda Kohn, Michael Miller, Nivedita Patni, et al.


  • Open Access

    Modified Delphi panel consensus recommendations for management of severe aplastic anemia

    by Daria V. Babushok, Amy E. DeZern, Carlos M. de Castro, Zora R. Rogers, David Beenhouwer, Michael S. Broder, Suzanne R. Fanning, Sarah N. Gibbs, Rabi Hanna, Jaroslaw P. Maciejewski, et al.

    Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled and, using the RAND/University of California, Los Angeles modified Delphi panel method, evaluated >600 varying patient care scenarios to develop clinical recommendations for the initial and subsequent management of patients of all ages with SAA. Here, we present the panel’s recommendations to rule out inherited bone marrow failure syndromes, on supportive care before and during first-line therapy, and on first-line (initial management) and second-line (subsequent management) therapy of acquired SAA, focusing on when transplant vs medical therapy is most appropriate. These recommendations represent the consensus of 11 experts informed by published literature and experience. They are intended only as general guidance for experienced clinicians who treat patients with SAA and are in no way intended to supersede individual physician and patient decision making. Current and future research should validate this consensus using clinical data. Once validated, we hope these expert panel recommendations will improve outcomes for patients with SAA.


  • Open Access

    Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria

    by David Dingli, Carlos De Castro Iii, Jamie Koprivnikar, Austin Kulasekararaj, Jaroslaw Maciejewski, Brian Mulherin, Jens Panse, Vinod Pullarkat, Alexander Röth, Jamile Shammo, et al.

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by the premature breakdown of red blood cells due to the ineffective inhibition of complement, a central part of the...


  • Open Access

    Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis

    by Morie Gertz, Rafat Abonour, Sarah N Gibbs, Muriel Finkel, Heather Landau, Suzanne Lentzsch, Grace Lin, Anuj Mahindra, Tiffany Quock, Cara Rosenbaum, et al.

    Purpose: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We used an expert panel to estimate healthcare utilization among advanced and non-advanced AL amyloidosis patients. Patients and Methods: Using the RAND/UCLA modified Delphi method, expert panelists completed 180 healthcare utilization estimates, consisting of inpatient and outpatient visits, testing, chemotherapy, and procedures by disease severity and organ involvement during two treatment phases (the 1 year after starting first line [1L] therapy and 1 year following treatment [post-1L]). Estimates were also provided for post-1L by hematologic treatment response (complete or very good partial response [CR/VGPR], partial, no response or relapse [PR/NR/R]). Areas of disagreement were discussed during a meeting, after which ratings were completed a second time. Results: During 1L therapy, 55% of advanced patients had ≥ 1 hospitalization and 38% had ≥ 2 admissions. Rates of hematopoietic stem cell transplant (HSCT) in advanced patients were 5%, while pacemaker or implantable cardioverter defibrillator (ICD) placement were 15%. During post-1L therapy, rates of hospitalization in advanced patients remained high (≥ 1 hospitalization: 20-43%, ≥ 2 hospitalizations: 10-20%), and up to 10% of advanced patients had a HSCT. Ten percent of these patients underwent pacemaker/ICD placement. Conclusion: Experts estimated advanced patients, who would not be good candidates for HSCT, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. The development of new treatment options that can facilitate organ recovery and improve function may lead to decreased utilization.


  • EPH25 Claims-Based Algorithms to Identify Persons with Severe Hemophilia A

    by R Khairnar, A Mahajerin, Ad Shapiro, R Sidonio, A Okolo, M Decker-Palmer, A Patel, Sn Gibbs, C Campos, M Broder, et al.

  • Top Cited Papers
    Open Access

    An Adaptation of the RAND/UCLA Modified Delphi Panel Method in the Time of COVID-19

    by Michael S Broder, Sarah N Gibbs, Irina Yermilov

    The RAND/UCLA modified Delphi panel method is a formal group consensus process that systematically and quantitatively combines expert opinion and evidence by asking panelists to rate, discuss, then re-rate items. The method has been used to develop medical society guidelines, other clinical practice guidelines, disease classification systems, research agendas, and quality improvement interventions. Traditionally, a group of experts meet in person to discuss results of a first-round survey. After the meeting, experts complete a second-round survey used to develop areas of consensus. During the COVID-19 pandemic, this aspect of the method was not possible. As such, we have adapted the method to conduct virtual RAND/UCLA modified Delphi panels. In this study, we present a targeted literature review to describe and summarize the existing evidence on the RAND/UCLA modified Delphi panel method and outline our adaptation for conducting these panels virtually. Transitioning from in-person to virtual meetings was not without challenges, but there have also been unexpected advantages. The method we describe here can be a cost-effective and efficient alternative for researchers and clinicians.


  • Open Access

    Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors

    by Xue Han, Francis Lobo, Michael S. Broder, Eunice Chang, Sarah N. Gibbs, David J. Ridley, Irina Yermilov

    Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling and destruction that leads to severe disability. There are no clear guidelines regarding the order of therapies. Gathering data on treatment patterns outside of a clinical trial setting can provide useful context for clinicians. Objectives: To assess real-world treatment persistence in early-line abatacept versus tumor necrosis factor-inhibitors (TNFi) treated patients with RA complicated by poor prognostic factors (including anti-cyclic citrullinated peptide antibodies [ACPA] and rheumatoid factor [RF] seropositivity). Methods: We performed a multi-center retrospective medical record review. Adult patients with RA complicated by poor prognostic factors were treated with either abatacept or TNFis as the first biologic treatment at the clinic. Poor prognostic factors included ACPA+, RF+, increased C-reactive protein levels, elevated erythrocyte sedimentation rate levels, or presence of joint erosions. We report 12-month treatment persistence, time to discontinuation, reasons for discontinuation, and risk of discontinuation between patients on abatacept versus TNFi. Select results among the subgroup of ACPA+ and/or RF+ patients are presented. Results: Data on 265 patients (100 abatacept, 165 TNFis) were collected. At 12 months, 83% of abatacept patients were persistent versus 66.1% of TNFi patients (P=0.003). Median time to discontinuation was 1423 days for abatacept versus 690 days for TNFis (P=0.014). In adjusted analyses, abatacept patients had a lower risk of discontinuing index treatment due to disease progression (0.3 [95% confidence interval (CI): 0.1-0.6], P=0.001). Among the subgroup of ACPA+ and/or RF+ patients (55 abatacept, 108 TNFis), unadjusted 12-month treatment persistence was greater (83.6% versus 64.8%, P=0.012) and median time to discontinuation was longer (961 days versus 581 days, P=0.048) in abatacept versus TNFi patients. Discussion: Patients with RA complicated by poor prognostic factors taking abatacept, including the subgroup of patients with ACPA and RF seropositivity, had statistically significantly higher 12-month treatment persistence and a longer time to discontinuation than patients on TNFis. Conclusions: In a real-world setting, RA patients treated with abatacept were more likely to stay on treatment longer and had a lower risk of discontinuation than patients treated with TNFis.


  • Open Access

    Development of a Severity Classification System for Sickle Cell Disease

    by Nirmish Shah, David Beenhouwer, Michael S Broder, Lanetta Bronte-Hall, Laura M De Castro, Sarah N Gibbs, Victor R Gordeuk, Julie Kanter, Elizabeth S Klings, Thokozeni Lipato, et al.

    Purpose: There is no well-accepted classification system of overall sickle cell disease (SCD) severity. We sought to develop a system that could be tested as a clinical outcome predictor. Patients and Methods: Using validated methodology (RAND/UCLA modified Delphi panel), 10 multi-disciplinary expert clinicians collaboratively developed 180 simplified patient histories and rated each on multiple axes (estimated clinician follow-up frequency, risk of complications or death, quality of life, overall disease severity). Using ratings on overall disease severity, we developed a 3-level severity classification system ranging from Class I (least severe) to Class III (most severe). Results: The system defines patients as Class I who are 8– 40 years with no end organ damage, no chronic pain, and ≤ 4 unscheduled acute care visits due to vaso-occlusive crises (VOC) in the last year. Patients < 8 or > 40 years with no end organ damage, no chronic pain, and < 2 unscheduled acute care visits are also considered Class I. Patients any age with ≥ 5 unscheduled acute care visits and/or with severe damage to bone, retina, heart, lung, kidney, or brain are classified as Class III (except patients ≥ 25 years with severe retinopathy, no chronic pain, and 0– 1 unscheduled acute care visits, who are considered Class II). Patients not meeting these Class I or III definitions are classified as Class II. Conclusion: This system consolidates patient characteristics into homogenous groups with respect to disease state to support clinical decision-making. The system is consistent with existing literature that increased unscheduled acute care visits and organ damage translate into clinically significant patient morbidity. Studies to further validate this system are planned.


  • The Humanistic and Economic Burden of Pediatric Focal Seizures in the United States

    by Sarah N. Gibbs, Jiyoon Choi, Ibrahim Khilfeh, K. Hamzah Ahmed, Irina Yermilov, Eric Segal

    Objective: To better understand the humanistic and economic burden of focal seizures in children 2-12 years old. Methods: We conducted a targeted literature review by searching MEDLINE for English-language publications reporting on children 2-12 years old with focal seizures published in the United States since 2008. Results: Thirty-five publications were included. Incidence of focal seizures was 23.2 to 47.1 per 100,000 children per year; prevalence was 2.0 per 1,000 children, and ranged from 1.6 - 2.6 per 1,000 in patients of any age. Life expectancy was 47.3-61.8 years among children 3-12 years old. Patients took several antiepileptic drugs and experienced frequent seizures, sleep disorders, mood disorders, migraine, and seizure-related injuries (eg, bone fractures, sprains, open wounds). Children with focal seizures scored below average on cognitive assessments and up to 42%, 16%, and 19% had depression, anxiety, and attention-deficit disorder, respectively. Patients of any age had about 10 outpatient visits (2 epilepsy-related), 2 inpatient visits (less than 1 epilepsy-related), and 24 procedures (1 epilepsy-related) per year. Medication adherence was low: only half of pediatric patients maintained ≥90% adherence over 6 months. Annual total health care costs among patients of any age ranged from $18,369 - 38,549; first-year total health care costs for children were $19,883. Conclusions: Incidence and prevalence of focal seizures is high and the humanistic and economic burdens are significant. Future studies focused exclusively on children with focal seizures are needed to more precisely describe the burden. We also suggest further research and implementation of methods to improve medication adherence as an approach to lessen burden on these young patients.


  • Open Access

    Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel

    by Nirmish Shah, David Beenhouwer, Michael S Broder, Lanetta Bronte-Hall, Laura De Castro, Sarah N Gibbs, Victor R Gordeuk, Julie Kanter, Elizabeth S Klings, Thokozeni Lipato, et al.

    Background: The clinical course of sickle cell disease (SCD) varies greatly by patient depending on age, complications, comorbidities, and psychosocial health. While researchers have developed models to predict complications and mortality, there is currently no accepted classification system of overall SCD severity. Our goal was to develop a severity classification system that could be tested for its ability to predict clinical outcomes. Methods: Using a RAND/UCLA modified Delphi panel, a method that has content, construct, and predictive validity, we convened 10 expert clinicians (9 MDs, 1 DNP) from various backgrounds (5 hematologist/oncologists, 3 internists, 1 psychiatrist/public health practitioner, 1 pulmonologist) with an average of 20 years of experience caring for SCD patients. Experts were provided with a review of evidence drawn from the 2014 National Heart, Lung, and Blood Institute Expert Panel Report, focusing on factors associated with morbidity and mortality in SCD. They collaboratively developed then rated 180 patient scenarios with varying characteristics (age, HbSS/HbSβ0/HbSC/HbSβ+ genotype, no/mild or moderate/severe end organ damage, presence/absence of chronic pain, and number of unscheduled acute care visits per year due to vaso-occlusive crises (VOCs)) on multiple axes including risk of complications or death, quality of life impact, and overall disease severity using a 1 to 9 scale. Each scenario was a simplified patient history in which end organ damage was defined as either severe damage to organs fed by the circulatory system (e.g., congestive heart failure, ≥Stage 3 kidney disease, overt stroke); mild/moderate damage (e.g., hypoxia, Stage 1 or 2 kidney disease, transient ischemic attack in the absence of stroke); or no damage. Other characteristics were also categorized in a simplified fashion (e.g., present/absent chronic pain defined as ongoing pain on most days over the past 6 months). Ratings were completed independently by each expert before an all-day in-person meeting. Areas of disagreement were discussed. Median ratings were grouped into 3 categories (1-3, 4-6, 7-9) and disagreement was defined as ≥2 individual ratings outside the median category. At the conclusion, experts completed ratings again. These final round ratings were used to develop a 3-level severity classification system ranging from Class I (least severe) to Class III (most severe). Results: The proportion of items with disagreement decreased from 64% to 32% following the meeting. In the final round, experts agreed on the overall disease severity of 77% of scenarios (Figure 1). Scenarios that differed only by hemoglobin genotype were rated similarly, with differences in the 0.0-0.4 range out of 9. Using final round ratings as a guide, experts agreed patients 8-40 years old with no end organ damage, no chronic pain, and ≤4 unscheduled acute care visits due to VOCs in the last year should be classified as Class I (least severe disease). Patients 40 years old with no end organ damage, no chronic pain, and <2 unscheduled acute care visits due to VOCs in the last year were also considered Class I. Patients any age with ≥5 unscheduled acute care visits due to VOCs in the last year were considered Class III (most severe disease). Similarly, patients any age with severe damage to bone, retina, heart, lung, kidney, or brain were classified as Class III, with the exception of patients ≥25 years old presenting with severe retinopathy, no chronic pain, and 0-1 unscheduled acute care visits due to VOCs in the last year, who were considered Class II. All other patients were classified as Class II (Table 1). Experts agreed that genotype does not affect classification. Conclusion: A validated methodology was used to assist a multi-disciplinary expert panel in developing a classification system for SCD severity, which could be implemented in a clinical setting. The system differs from earlier prediction models of disease severity: Instead of estimating mortality risk using mathematical modeling, it consolidates patient characteristics into homogenous groups of patients with respect to disease state to support clinical decision-making. The system is consistent with existing literature that increased unscheduled acute care visits and organ damage translate into clinically significant patient morbidity. Studies to further validate this system using patient reported and clinical outcomes are planned. Disclosures Shah: GBT: Research Funding; Alexion: Speakers Bureau; Novartis: Consultancy, Research Funding, Speakers Bureau. Beenhouwer:Partnership for Health Analytic Research (PHAR), LLC: Other: I am an employee of the Partnership for Health Analytic Research (PHAR), LLC, which was paid by Novartis to conduct the research described in this . Broder:Partnership for Health Analytic Research (PHAR), LLC: Other: I am an employee of the Partnership for Health Analytic Research (PHAR), LLC, which was paid by Novartis to conduct the research described in this . Bronte-Hall:Novartis: Consultancy. De Castro:Pfizer: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees. Gibbs:Partnership for Health Analytic Research (PHAR), LLC: Other: I am an employee of the Partnership for Health Analytic Research (PHAR) LLC, which was paid by Novartis to conduct the research described in this . Gordeuk:CSL Behring: Consultancy, Honoraria, Research Funding; Emmaus: Consultancy, Honoraria; Global Blood Therapeutics: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Modus Therapeutics: Consultancy, Honoraria; Pfizer: Research Funding; Inctye: Research Funding; Ironwood: Research Funding; Imara: Research Funding. Kanter:Rockpointe: Honoraria; Medscape: Honoraria; Sangamo: Consultancy; GLG: Consultancy; SCDAA:...